Fatty15’s marketing frequently references ‘clinical trial’ data, which can imply more than what the underlying study actually establishes. The core published human trial is real, peer-reviewed, and worth reading closely, but understanding its design tells you a lot about what it can and can’t support as a claim.
This breaks down the trial’s actual structure: who was studied, what was measured, what the results were, and where the limits of that evidence sit.
The Trial’s Basic Design
The relevant study is a single-center, double-blind, randomized, placebo-controlled, two-arm trial published in The Journal of Nutrition, registered at ClinicalTrials.gov [1]. Thirty young adults with overweight or obesity (mean age about 20, mean BMI about 33) were randomized, with 20 receiving 200 mg of C15 daily and 10 receiving a placebo, for 12 weeks.
That’s a real randomized controlled trial, the gold-standard design for testing causation, but the sample size (30 total participants) is small even by early-phase supplement trial standards, and it was conducted at a single site, which limits how confidently the results generalize to other populations.
What the Trial Actually Measured
The trial’s primary objective was to see whether daily C15 supplementation raised circulating C15 levels, essentially a pharmacokinetic and safety question, not a disease-outcome question. Secondary measurements tracked safety, tolerability, and a handful of physiological markers like liver enzymes and hemoglobin.
Research note: A narrative review describes a 12-week double-blind trial where 200 mg/day of purified C15:0 raised plasma levels and tended to lower non-HDL cholesterol and triglycerides without raising LDL-C [9].
It found that circulating C15 rose significantly more in the treatment group than placebo, and that no significant adverse events occurred over the 12 weeks. Among participants who reached a higher circulating C15 threshold (above 5 µg/mL) after treatment, there were larger reductions in liver enzymes ALT and AST and a modest rise in hemoglobin compared to those who didn’t reach that threshold [1].
What This Trial Does Not Establish
This design cannot tell you whether C15 prevents disease, extends lifespan, or produces the broad anti-aging benefits implied in some marketing copy: it wasn’t statistically powered to detect those outcomes, and it didn’t measure them over a long enough window even if it had been. The liver-enzyme and hemoglobin findings are described by the authors as signals warranting further study, not proven clinical benefits; they came from a subgroup split made after treatment (participants above vs. below a threshold), which is a weaker form of evidence than a pre-specified primary endpoint.
Two details sharpen those limits. The trial was supported by Seraphina Therapeutics, which supplied the capsules. And apart from a drop in the liver enzyme GGT, it found no other significant differences between C15 and placebo in any secondary outcome, so the enzyme and hemoglobin signals appeared only in the post-hoc subgroup [1].
It also can’t establish long-term safety. Twelve weeks in 20 treated participants is enough to rule out obvious, common short-term adverse effects, but not rare ones, and not anything that might emerge over years of daily use.
What Each Kind of C15 Study Can and Cannot Tell You
Much of the early C15 literature measured blood levels in large groups and looked for correlations with health outcomes. People who eat more full-fat dairy differ from others in many ways, so those studies point to associations, not proof that C15 caused a result. Intervention trials can test cause and effect more directly, but the two published so far are small and short. Claims that cite a single trial as definitive proof deserve caution for that reason.
| Study Type | What It Can Tell Us | Limitation |
|---|---|---|
| Observational | Associations between blood C15 and outcomes | Cannot prove causation |
| Small intervention trial | Direct effect of supplementation on markers | Small sample sizes, short duration |
| Animal and cell studies | Mechanistic plausibility | Does not guarantee human results |
Neither human trial measured a hard outcome such as a heart attack, a diagnosis or lifespan, and neither has been replicated, so current evidence speaks to short-term biological markers, not long-term disease prevention.
How This Fits the Broader Evidence Base
This trial sits alongside a larger body of preclinical and cell-based research: the original dolphin-derived discovery work [2], comparative cell-system studies against omega-3 [3], and observational cohort associations: that together make C15 a genuinely interesting research subject. But the human clinical evidence specifically is still at an early, small-sample stage. A single 30-person trial establishing safety and pharmacokinetics is a reasonable first step in a research program; it is not, on its own, proof of the health claims built on top of it.
Reading the Numbers in the Abstract
The trial is registered as NCT04947176 and its abstract gives enough detail to check how the headline claims map onto the data. Participants had a mean age of 20.0 years (standard deviation 2.1) and a mean body mass index of 33.4. The primary objective was a change in plasma C15 after 12 weeks. The mean rise in the treatment group was 1.88 micrograms per milliliter greater than in the placebo group (P = 0.003), and no significant adverse events occurred. That is the pre-stated result: on 200 mg a day blood C15 rose more than on placebo, though the absolute gap was small [1].
Half of the 20 treated participants, so about 10 people, ended with a blood level above 5 micrograms per milliliter. Within that group, alanine aminotransferase fell by 29 units per liter (P = 0.001), aspartate aminotransferase fell by 6 (P = 0.014), and hemoglobin rose by 0.60 grams per deciliter (P = 0.010), compared with participants who did not reach that level. The authors’ own conclusion is careful: levels above 5 were associated with “potentially relevant improvements in clinical indices, warranting further study.” Notice the verb. They wrote associated, not caused.
Why a Subgroup Split Is Weaker Than the Randomization
Randomization is what makes a trial powerful: chance decides who gets the capsule, so the two groups should differ only in treatment. The split at 5 micrograms per milliliter is a different kind of comparison. Nobody was randomized to a high or low blood level. People ended up there because of how much they absorbed or metabolized, what they ate, their body size, how faithfully they took the capsules, and other factors that could also influence liver enzymes and hemoglobin. When a subgroup is defined by an outcome-like measurement after treatment starts, the comparison can reflect those underlying differences rather than the supplement itself.
A second issue is numbers. With roughly 10 people in the high group and the rest of the treated arm, plus 10 placebo participants, a handful of individuals can move a group average. The abstract does not state whether the enzyme comparison included the placebo group, so it is worth reading the full paper before leaning on it. None of this makes the observation uninteresting. It makes it a hypothesis that a larger trial can test by pre-specifying a target blood level and measuring the same outcomes.
What 200 mg Means Next to a Fatty15 Capsule
The trial used 200 mg of C15 daily. On its product page, read in October 2026, Fatty15 lists 100 mg of pure C15 per capsule, so the trial dose corresponds to two capsules a day. The company’s FAQ recommends starting with one capsule daily, so the trial dose is double that starting point. The trial also does not tell you what blood level a person reaches on one capsule, and individual response varied enough in the study that only half of treated participants passed 5 micrograms per milliliter at the higher dose. Anyone interpreting the trial should keep that in mind before assuming the dose on the label reproduces the findings.
How This Trial Compares With the Other Human Evidence
Four other lines of human evidence get mentioned alongside this trial, and they answer different questions.
- A second randomized trial. The TANGO trial, published in the American Journal of Clinical Nutrition in 2024 (Chooi et al.), randomized 88 Chinese women with fatty liver disease to a Mediterranean-style diet with C15 (31 women), the same diet without C15 (28), or their usual diet (29) for 12 weeks. Both diet groups improved on weight, liver fat and several lipid markers compared with usual diet, and the C15 group had a further reduction in LDL cholesterol. Liver fat (proton density fat fraction) fell by 33% with diet plus C15, 30% with diet alone and 10% with usual diet, so the liver-fat benefit tracked the diet rather than the supplement.[4] Because the comparison of interest is diet with C15 against diet alone, the supplement’s contribution is isolated, but the abstract reports it only for LDL cholesterol and a shift in one gut bacterium, Bifidobacterium adolescentis. The trial tested C15 alongside a diet change, which is not the same as supplementing in isolation.
- A mood analysis of TANGO. A 2025 Frontiers in Nutrition paper reported anxiety and depression scores for 84 of the TANGO women (29 on diet plus C15, 26 on diet alone, 29 on usual diet). It found significant reductions within the groups, including a fall in trait anxiety in the diet plus C15 group from a mean of 38.62 to 34.10 (p < 0.001). Those are paired tests of each group against its own baseline. They show that scores moved over 12 weeks, not that the C15 arm improved more than the diet-only arm, and the abstract does not report that between-arm comparison. Its conclusion credits the Asian-adapted diet rather than the supplement, describes the mood work as a secondary analysis, and asks for caution and larger samples.[6]
- Large cohort studies. A 2018 PLOS Medicine pooled analysis of 16 prospective cohorts (63,682 participants, 15,180 incident type 2 diabetes cases) found that higher circulating levels of C15 were associated with lower diabetes incidence, with a hazard ratio of 0.80 across the 10th to 90th percentile range. These studies measure blood levels as biomarkers of dairy fat intake, and the authors note they cannot separate dairy sources and that residual confounding may exist. They show an association, not that adding a capsule lowers risk.
- Cell and animal work. The 2020 Scientific Reports paper (Venn-Watson, Lumpkin and Dennis), by authors linked to the C15 supplement maker, proposed that C15 could be a potential essential fatty acid, based on animal studies and population evidence, and stated that further studies are needed. An independent mini-review calls the essentiality of pentadecanoic acid controversial [2][7].
What the Marketing Says Versus What the Trial Shows
Fatty15’s product page, as of October 2026, describes more than 10 years of research with the U.S. Navy and more than 150 peer-reviewed studies. Those are brand statements, and the number of studies is not the same as the number of human trials of the capsule, which is currently the one described here plus TANGO. When you see a claim tied to “clinical trial data,” ask three questions: how many people, for how long, and which outcome was the one the study was designed to measure. For the Journal of Nutrition trial the answers are 30 people, 12 weeks, and blood C15. For liver enzymes, hemoglobin, appetite, sleep or mood, the answer is that they were secondary or exploratory measurements.
What a Stronger Follow-Up Would Look Like
A trial that could settle these questions would need a larger sample, a longer duration, a pre-specified clinical primary outcome such as liver fat or enzyme change, and either a dose-response design or a target blood level written into the protocol before enrolment. It would also need participants beyond young adults with obesity, since the trial mean age was 20. Until then, the fair summary is that C15 raised blood C15, appeared well tolerated at 200 mg over 12 weeks in a small group, and produced exploratory signals worth chasing.
How many people were in the C15 clinical trial that Fatty15 cites [8]?
The 2024 Journal of Nutrition randomized trial had 30 participants, 20 on 200 mg of C15 per day and 10 on placebo, followed for 12 weeks.
Was the liver enzyme improvement in the trial a proven effect?
No. It was seen when participants were grouped by whether their blood C15 ended above 5 micrograms per milliliter, a grouping that was not randomized. The authors called it associated with potentially relevant improvements and said it warrants further study.
Has any C15 trial shown that it prevents disease?
No. The two randomized supplementation trials each ran 12 weeks in a few dozen people and measured biological markers, not disease outcomes, and neither was designed or powered to show prevention.
Is the trial dose the same as one Fatty15 capsule?
No. The trial used 200 mg daily, while the Fatty15 product page lists 100 mg of C15 per capsule, so the trial dose equals two capsules.
References
- Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of Nutrition, 2024
- Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?. Scientific Reports, 2020
- Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3. PLOS ONE, 2022
- Chooi YC et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. The American journal of clinical nutrition (2024). PMID 38035997
- Imamura F et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS medicine (2018). PMID 30303968
- Salamanca-Sanabria A et al. Potential effects of Asian-adapted Mediterranean diet in depression and anxiety among women with metabolic dysfunction-associated steatotic liver disease: a secondary analysis. Frontiers in nutrition (2025). PMID 40697557
- Ciesielski V et al. New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review. Biochimie (2024). PMID 39395658
- Fatty15 (Seraphina Therapeutics) Fatty15 FAQs. Fatty15 (Seraphina Therapeutics) (2026). source
- Mercola J Pentadecanoic acid (C15:0) and cardiovascular disease: A narrative review. World journal of cardiology (2025). PMID 41480001
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.